

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6450475

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
KREOS CAPITAL V (UK) LIMITED	12/15/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEREO BIOPHARMA 5, INC.
<b>Street Address:</b>	800 CHESAPEAKE DR
<b>City:</b>	REDWOOD CITY
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94063
<b>PROPERTY NUMBERS Total: 16</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7750124
Patent Number:	9376497
Patent Number:	9228020
Patent Number:	9067986
Patent Number:	9309311
Patent Number:	9914771
Patent Number:	8883145
Patent Number:	9511139
Patent Number:	9982042
Patent Number:	8551479
Patent Number:	9480744
Patent Number:	8858941
Patent Number:	9376488
Patent Number:	9574009
Patent Number:	9879084
Patent Number:	9599620
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)778-5393
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

PATENT

**Phone:** 2026625393  
**Email:** lstaubach@cov.com  
**Correspondent Name:** LINDSEY STAUBACH  
**Address Line 1:** 850 10TH ST NW  
**Address Line 2:** 691S  
**Address Line 4:** WASHINGTON, D.C. 20001

<b>ATTORNEY DOCKET NUMBER:</b>	038081.00010
<b>NAME OF SUBMITTER:</b>	LINDSEY STAUBACH
<b>SIGNATURE:</b>	/Lindsey Staubach/
<b>DATE SIGNED:</b>	12/15/2020

**Total Attachments: 5**

source=Mereo\_Kreos\_-\_Release\_of\_Patent\_Security\_Interest\_-\_Execution\_Version\_297411046\_2#page1.tif  
source=Mereo\_Kreos\_-\_Release\_of\_Patent\_Security\_Interest\_-\_Execution\_Version\_297411046\_2#page2.tif  
source=Mereo\_Kreos\_-\_Release\_of\_Patent\_Security\_Interest\_-\_Execution\_Version\_297411046\_2#page3.tif  
source=Mereo\_Kreos\_-\_Release\_of\_Patent\_Security\_Interest\_-\_Execution\_Version\_297411046\_2#page4.tif  
source=Mereo\_Kreos\_-\_Release\_of\_Patent\_Security\_Interest\_-\_Execution\_Version\_297411046\_2#page5.tif

## **RELEASE OF SECURITY INTEREST IN PATENTS**

This RELEASE OF SECURITY INTEREST IN PATENTS (this “**Release**”) is made and effective as of December 15, 2020 and granted by KREOS CAPITAL V (UK) LIMITED (together with its Affiliates, successors, transferees and assignees, the “**Security Agent**”), as the Security Agent under the Security Agreement referred to below, in favor of MEREIO BIOPHARMA 5, INC. (f/k/a ONCOMED PHARMACEUTICALS, INC.), a Delaware corporation (the “**Grantor**”), and its successors, assigns and legal representatives.

WHEREAS, pursuant to that certain Security Agreement, dated as of July 19, 2019 (as amended, supplemented or otherwise modified from time to time, the “**Security Agreement**”), by and between the grantors party thereto (including the Grantor) and the Security Agent, the Grantor executed and delivered to the Security Agent that certain Notice of Grant of Security Interest in Patents (the “**Patent Security Agreement**” and together with the Security Agreement, the “**Security Agreements**”);

WHEREAS, pursuant to the Security Agreements, the Grantor pledged and granted to the Security Agent for its benefit a security interest in and to all of the right, title and interest of such Grantor in, to and under all of the patents, patent licenses and patent applications set forth on Schedule I of the Patent Security Agreement (the “**Patent Collateral**”);

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office at Reel 049807, Frame 0948; and

WHEREAS, the Security Agent wishes to provide a document evidencing the release, relinquishment and discharge of its security interest in the Patent Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Security Agent hereby states as follows:

1. Release of Security Interest. The Security Agent, on behalf of itself and its successors, legal representatives and assigns, hereby terminates the Patent Security Agreement and terminates, releases and discharges any and all security interests that it has pursuant to the Patent Security Agreement in any and all right, title and interest of the Grantor, and reassigns to the Grantor any and all right, title and interest that it may have, in, to and under the Patent Collateral (including the patents and patent licenses listed on **Schedule 1** hereto).
2. Authorization. The Security Agent hereby authorizes and requests the United States Patent and Trademark Office and any other applicable government officer to record this Release.

3. Further Assurances. The Security Agent agrees, at the Grantor's expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.


3. Execution in Counterparts. This Release may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts taken together shall be deemed to constitute one and the same instrument. Telecopied signatures hereto shall be of the same force and effect as an original of a manually signed copy.

4. Governing Law. **THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE UNITED STATES AND THE STATE OF NEW YORK WITHOUT REFERENCE TO ANY CHOICE OR CONFLICT OF LAW DOCTRINE THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.**

*[Signature Page Follows]*

**IN WITNESS WHEREOF**, the Security Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

**KREOS CAPITAL V (UK) LIMITED**

By:  DocuSigned by:  
475E5D0992AF4C5...

Name: Maurizio PetitBon

Title: Director

# SCHEDULE 1

## Patents and Patent Licenses

### ONCOMED NAVICIXIZUMAB – US PORTFOLIO CASES (JUNE 2019)

#### OMP-025

ANTI-HUMAN DLL4 ANTIBODIES AND COMPOSITIONS / COMPOSITIONS AND METHODS  
FOR DIAGNOSING AND TREATING CANCER

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-025NP1	USA	11/905,392	09/28/2007	7,750,124	07/06/2010	Granted
OMP-025CON1	USA	12/782,429	05/18/2010	9,376,497	06/28/2016	Granted
OMP-025C1D1	USA	13/826,103	03/14/2013	9,228,020	01/05/2016	Granted

#### OMP-054

METHOD FOR MAKING HETEROMULTIMERIC MOLECULES

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-054NP1	USA	12/768,650	04/27/2010	9,067,986	06/30/2015	Granted
OMP-054NP1D1	USA	13/801,189	03/13/2013	9,309,311	04/12/2016	Granted
OMP-054NP1DIV1	USA	15/059,668	03/03/2016	9,914,771	03/13/2018	Granted

#### OMP-61

THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WITH A DLL4 ANTAGONIST  
AND AN ANTI-HYPERTENSIVE AGENT/ THERAPEUTIC COMBINATION AND USE OF DLL4  
ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-061NP1	USA	13/501,944	10/18/2010	8,883,145	11/11/2014	Granted
OMP-061NP1DIV1	USA	14/498,602	09/26/2014	9,511,139	12/06/2016	Granted
OMP-061NP1DIV2	USA	15/336,272	10/27/2016	9,982,042	05/29/2018	Granted

**OMP-078****METHOD FOR TREATING MELANOMA**

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-078NP1	USA	13/229,006	09/09/2011	8,551,479	10/08/2013	Granted
OMP-078NP1CON1	USA	14/020,567	09/06/2013	9,480,744	11/01/2016	Granted

**OMP-084**

VEGF/DLL4 BINDING AGENTS AND USES THEREOF/ VEGF BINDING ANTIBODIES/ MODIFIED IMMUNOGLOBULIN MOLECULES THAT SPECIFICALLY BIND HUMAN VEGF AND DLL4 / POLYNUCLEOTIDES ENCODING VEGF/DLL4 BINDING AGENTS

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-084NP1	USA	13/625,417	09/24/2012	8,858,941	10/14/2014	Granted
OMP-084DIV1	USA	14/476,582	09/03/2014	9,376,488	06/28/2016	Granted
OMP-084DIV2	USA	15/163,301	05/24/2016	9,574,009	02/21/2017	Granted
OMP-084DIV3	USA	15/401,543	01/09/2017	9,879,084	01/30/2018	Granted

**OMP-098****METHODS AND MONITORING OF TREATMENT WITH A DLL4 ANTAGONIST**

<i>Our ref</i>	<i>Country</i>	<i>Application No.</i>	<i>Application Date</i>	<i>Patent No.</i>	<i>Grant Date</i>	<i>Status</i>
OMP-098NP2	USA	14/068,910	10/31/2013	9,599,620	03/21/2017	Granted